PARP inhibitors in metastatic breast cancer: The present and the future

The challenge of detecting NTRK fusions across tumour types

The latest research highlights in lymphoma

GORTEC: Cisplatin chemoradiation plus debio 1143 in patients with locally advanced head and neck squamous cell carcinoma

Shaping the future of metastasis - ecancer investigates

Realising the potential of biosimilars

Comment: Supporting a sustainable biosimilar solution

Comment: Use of biosimilar monoclonal antibodies in the clinic

Comment: Critical quality attributes of biosimilars

TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens or immunotherapy

CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer